Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 685 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Eczema Atopic Dermatitis Clear all

Conditions: Atopic Dermatitis
Interventions: Apremilast; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib (ABT-494); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more

Conditions: Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions: PF-06817024, Placebo for PF-06817024; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab Prefilled Syringe, Rocatinlimab AI; Combination Product
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Atopic Dermatitis, Sleep Disturbance
Interventions: Dupilumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Atopic Dermatitis
Interventions: Skin Biopsy, Skin tape stripping, Blood draw; Procedure
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: Dermatitis, Atopic
Interventions: AN2728 Topical Ointment, 2%, Matching vehicle control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 763 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stockbridge, Georgia

Conditions: Atopic Dermatitis
Interventions: OpSCF, Placebo; Biological
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more

Conditions: Chronic Hand Eczema
Interventions: ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Beverly Hills, California • Encino, California • Fremont, California + 21 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1%; Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Months and older
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Atopic Dermatitis
Interventions: SAR444656 (KT-474), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Boynton Beach, Florida • Doral, Florida • Hollywood, Florida + 4 more

Conditions: Eczema, Atopic Dermatitis
Interventions: Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device); Device
Lead sponsor: Frankel, Amylynne, M.D.; Other
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Interventions: Blood draw, skin biopsy or urine collection; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy, Atopic Dermatitis
Interventions: Trier Social Stress Test (TSST), Landscape Video; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions: Tofacitinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Eczema, Atopic Dermatitis, Eczema-Prone Skin
Interventions: Rejuvaskin Eczema Body Wash; Dietary Supplement
Lead sponsor: Rejuvaskin; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment, Vehicle ointment; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Placebo (for Dupilumab); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more

Conditions: Alopecia Areata
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Hydrogel vehicle, Eucerin Lotion; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

A Study in Subjects With Moderate Atopic Dermatitis

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Stress-induced Scratching in Healthy and AD

Tofacitinib for Immune Skin Conditions in Down Syndrome

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis